Conspicuously, CMS included drugs that could face imminent generic or biosimilar competition before 2026, which is when the negotiated prices first go into effect.
Conspicuously, CMS included drugs that could face imminent generic or biosimilar competition before 2026, which is when the negotiated prices first go into effect.